Medtronic Invests Up to $80 Million in Pi-Cardia
Medtronic and Pi-Cardia announced in a press release that Medtronic will make strategic investments of up to $80 million in Pi-Cardia. The agreement gives Medtronic an option to expand its structural heart portfolio and is expected to make Medtronic the exclusive global commercial distributor of Pi-Cardia's ShortCut device in 2027.
ShortCut is an FDA cleared leaflet modification device for transcatheter aortic valve replacement procedures in patients at risk of coronary obstruction. Pi-Cardia said the device is designed to split valve leaflets and help preserve coronary access during future transcatheter valve procedures.
The agreement also gives Medtronic an option to acquire Pi-Cardia after predefined milestones are met. The upfront acquisition price could reach $210 million, subject to adjustments, with additional payments possible after acquisition. The transactions require regulatory approval and other closing conditions.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Enterprise AI Brief, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from: Enterprise
More from: Funding
Subscribe to Enterprise AI Brief
Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more